Roivant Sciences Ltd
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +254.0% | -1.2% | -14.1% | +0.0% | -6.7% | -6.1% | -7.4% | +0.6% | +3.2% | +9.6% | -7.4% | |
| – | +338.7% | -1.1% | -13.8% | +0.0% | -7.5% | -6.8% | -7.7% | -2.3% | +3.3% | +10.9% | -8.2% | |
| – | +371.9% | -2.0% | -70.0% | +0.0% | +1.6% | +36.4% | -54.4% | -0.1% | +19.5% | -3.7% | -12.3% | |
| – | +371.9% | -1.9% | -17.6% | +0.0% | -4.5% | -5.0% | -7.9% | -2.6% | +3.3% | -5.2% | -10.6% | |
| – | +15.7% | +31.1% | -72.6% | +0.0% | +533.8% | – | – | – | – | – | +0.4% | |
| – | +6.8% | +572.7% | -3.6% | -666.3% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +7.0% | -8.4% | -1.3% | – | – | – | – | – | – | – | – | |
| – | -1.6% | +6.3% | -19.1% | +0.0% | -59.0% | -2.6% | -13.2% | +18.7% | -2.3% | +73.5% | -11.7% | |
| – | -7.8% | +8.9% | +108.5% | +0.0% | -74.6% | +5.6% | -23.8% | +17.6% | +13.5% | +85.1% | +0.8% | |
| – | -6.2% | -61.0% | -56.5% | +0.0% | +3.3% | +0.1% | -4.5% | -4.3% | +15.9% | +6.8% | +11.1% | |
| – | -20.2% | +51.1% | -52.8% | +0.0% | -5.6% | -0.1% | -51.2% | +30.4% | -11.7% | +35.4% | +39.3% | |
| – | +3.6% | +6.8% | -27.6% | – | – | – | – | – | – | – | – | |
| – | +542.0% | -2.0% | -13.7% | +0.0% | +0.7% | -9.7% | -7.3% | +0.4% | -2.1% | +6.0% | -6.5% | |
| – | – | -20.8% | -31.3% | +0.0% | +16.4% | -74.8% | -371.9% | – | – | – | – | |
| – | +9.6% | -4.9% | -8.4% | +0.0% | -1.7% | -2.1% | -3.8% | +0.1% | +2.3% | +16.6% | -11.3% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.